

References

1. Loomis CA, Birge MB. Fetal skin development. In: Eichenfield LF, Frieden IJ, Esterly NB (Hrsg). *Textbook of Neonatal Dermatology*. Philadelphia: WB Saunders 2001; 1:17.
2. Elias PM. Epidermal lipids, barrier function, and desquamation. *J Invest Dermatol* 1993; 80 (Suppl.): 44S-49S
3. Feingold KR. The regulation and role of epidermal lipid synthesis. *Advan Lipid Res* 1991; 24: 57-82
4. Forslind B. A domain mosaic model of the skin barrier. *Acta Derm Venerol* 1999; 74: 72-77
5. Behne MJ, Barry NP, Hanson KM, Aronchik I, Clegg RW, Grattan E, Feingold K, Molleran WM, Elias PM, Mauro TM. Neonatal development of the stratum corneum pH gradient: localization and mechanisms leading to emergence of optimal barrier function. *J Invest Dermatol* 2003; 120: 998-1006.
6. Fluhr JW, Behne MJ, Brown BE, Moskowitz DG, Selden C, Mao-Qiang M, Mauro TM, Elias PM, Feingold KR. Stratum corneum acidification in neonatal skin: secretory phospholipase A2 and the sodium/hydrogen antiporter-1 acidify neonatal rat stratum corneum. *J Invest Dermatol* 2004; 122: 320-329.
7. Chapman SJ, Walsh A. Membrane-coating granules are acidic organelles which posses proton pumps. *J Invest Dermatol* 1989; 93: 466-470
8. Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal barrier homeostasis, and stratum corneum integrity/ cohesion. *J Invest Dermatol* 2003; 121: 345-353.
9. Yoipovitch G. Dry skin and impairment of barrier function associated with itch – new insights. *Int J Cosmetic Sci* 2004; 26: 1-7.
10. Hildebrandt D, Ziegler K, Wollina U. Electrical impedance and transepidermal water loss of healthy human skin under different conditions. *Skin Res Technol* 1998; 4: 130-134.
11. Kligman AM. Hydration injury to human skin: a view from the horny layer. In: *Handbook of Occupational Contact Dermatitis*. Kanerva L, Elsner P, Wahlberg JE, Maibach HI (Hrsg). Berlin – Heidelberg – New York: Springer 2000, 76-80.
12. Grubauer G, Elias PM, Feingold KR: Transepidermal water loss: The signal for recovery of barrier structure and function. *J Lipid Res* 1989; 30: 323-333.
13. Draelos Z. Therapeutic moisturisers. *Dermatol Clin* 2000; 18: 597-606.
14. Motta S, Monti M, Rigano L. Polydecene oligomers versus mineral oils: The rationale of use in dermatological preparations. In: Yazan Y (Hrsg). *Skin Care and Aesthetics in the Millennium*. Istanbul: ESCAD & TCOS 2003: 101-104.
15. Gabard B, Chantelain E. Concentration of urea in the stratum corneum and moisturizing effect. *Trends Clin Exp Dermatol* 2003; 2: 27-36.
16. Loftsson T. Cyclodextrins in skin delivery. *Cosmet Toilet* 2000; 115: 59-66.
17. Chiu A, Kimball AB. Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. *Br J Dermatol* 2003; 149: 681-691.
18. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexamethasone in skin disorders. *Am J Clin Dermatol* 2002; 3: 427-433.
19. Girard P, Berand A, Goujou C, Sirvent A, Foyatier J-L, Alleaume B, de Bony R. Effect of Bepanthen® Ointment on the graft-donor site wound-healing model: double-blind biometrical and clinical study, with assessment by the patient, versus the vehicle. *Nouv Dermatol* 1998; 17: 559-570.
20. Girard P, Goujou C, Violin L, de Bony R, Foyatier JL. A double-blind biometrical, histological, clinical and patient evaluation pilot study of the effect of Bepanthen® Ointment versus excipient using a skin graft donor site as a wound healing model. *Nouv Dermatol* 1997; 16: 266-275.
21. Gehring W, Gloor M. Die Bedeutung von topisch appliziertem Dexamethasone für die epidermale Barrierefunktion und die Hydratation des Stratum corneum. *Arzneim-Forsch/ Drug Res* 2000; 50(II): 659-663.
22. Gehring W, Gloor M. Der Effekt von Dexamethasone bei experimentell geschädigter Haut. *Z Hautkrankh* 2001; 76: 212-218.
23. Wollina U, Nissen H-P, Kubicki J. Anti-entzündliche Wirkungen von Dexpanthenol. *Akt Dermatol* 2004; 30: 478-482.
24. Schmuth M, Sztankay A, Weinlich G, Linder DM, Wimmer MA, Fritsch PO, Fritsch E. Permeability barrier function of skin exposed to ionizing radiation. *Arch Dermatol* 2001; 137: 1019-1023.
25. Ratliff C. Impaired skin integrity related to radiation therapy. *J Enterostomal Ther* 1990; 17: 193-198.
26. Zimmermann JS, Budach W, Dörr W. Individual skin care during radiation therapy. *Strahlenther Onkol* 1998; 174 [Suppl 3]: 74-77.
27. Porock D, Kristjanson L. Skin reactions during radiotherapy for breast cancer: the use and impact of topical agents and dressings. *Eur J Cancer Care (Engl)* 1999; 8: 143-153.
28. Szumacher E, Wighton A, Franssen E, Chow E, Tsao M, Ackerman I, Andersson L, Kim J, Wojcicka A, Ung Y, Sixel K, Hayter C. Phase II study assessing the effectiveness of Bifine cream as prophylactic agent for ration-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapy. *Int J Radiol Oncol Biol Phys* 2001; 51: 81-86.
29. Fisher J, Scott C, Stevens R, Marconi B, Champion L, Freedman GM, Asrari F, Pilepich MV, Gagnon JD, Wong G. Randomized phase III study comparing Best Supportive Care to Bifine as a prophylactic agent for radiation-

- induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13. *Int J Radiat Oncol Biol Phys* 2000; 48: 1307-1310.
30. Roy I, Fortin A, Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized study. *Radiother Oncol* 2001; 58: 333-339.
31. Olsen DL, Raub Jr W, Bradley C, Johnson M, Macias JL, Love V, Markoe A. The effect of aloe vera gel/ mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy. *Oncol Nurs Forum* 2001; 28: 543-547.
32. Slyshenkov VS, Omelyanchik SN, Moiseenok AG, Petushok NE, Wojtczack L. Protection by panthenol and beta-carotene against liver damage produced by low-gamma radiation. *Acta Biochim Pol* 1999; 46: 239-248.
33. Schratter-Sehn AU, Brinda K, Kahrer M, Novak M. Improvement of skin care during radiotherapy. *Onkologie* 2001; 24: 44-46.
34. Lokkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G. Skin treatment with bepanthen cream versus no cream during radiotherapy - a randomized controlled trial. *Acta Oncol* 1996; 35: 1021-1026.
35. Bostrom A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces radiation dermatitis: results from a double-blind, randomized study. *Radiother Oncol* 2001; 59: 257-265.
36. Panizzon RG, Mirimanoff R-O. *Hautpflege bei Tiefenbestrahlung*. *Hautarzt* 2001; 52: 150.
37. Roth RR, James WD. Microbial ecology of the skin. *Annu Rev Microbiol* 1988; 42: 441-464.
38. Soll RF, Edwards WH. Emollient ointment for preventing infection in preterm infants. *Cochrane Database* 2000; Syst Rev CD 001150
39. Rhody C. Bacterial infections of the skin. *Prim Care* 2000; 27: 459-473.
40. Wollina U. Contact allergy associated with topical treatment. In: Gebhardt M, Elsner P, Marks Jr JG (Hrsg). *Handbook of Contact Dermatitis*. London: Martin Dunitz; 2000:71-81.
41. Lazarus MC, Kerdel FA. Topical tacrolimus Protopic. *Drugs Today (Barc)* 2002; 38: 7-15.
42. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. *Expert Opin Pharmacother* 2004; 5: 643-655.
43. Nicolas P, Vanhoye D, Amiche M. Molecular strategies in biological evolution of antimicrobial peptides. *Peptides* 2003; 24: 1669-1680.
44. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. *J Leukoc Biol* 2004; 75: 39-48.
45. Mangoni ML, Papo N, Mignogna G, Andreu D, Shai Y, Barra D, Simmaco M. Ranacyclins, a new family of short cyclic antimicrobial peptides: biological function, mode of action, and parameters involved in target specificity. *Biochemistry* 2003; 42: 14023-14035.
46. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. *J Invest Dermatol* 2002; 119: 1090-1095.
47. Oren A, Ganz T, Liu L, Meerloo T. In human epidermis, beta-defensin 2 is packed in lamellar bodies. *Exp Mol Pathol* 2003; 74: 180-182.
48. Schittek B, Hipfel R, Sauer B, Bauer J, Kallenbacher H, Stevanovic S, Schirle M, Schroeder K, Blin N, Meier F, Rassner G, Garbe C. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. *Nat Immunol* 2001; 2: 1133-1137.
49. Dorschner RA; Lin KH, Murakami M, Gallo RL. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. *Pediatr Res* 2003; 53: 566-572.
50. Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jornvall H, Marchini G, Agerberth B. Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. *Pediatr Res* 2003; 53: 211-216.
51. Sorensen OE, Cowland JB, Theilgaard-Mönch K, Liu L, Ganz T, Borregaard N. Wound healing and expression of antimicrobial peptides/ polypeptides in human keratinocytes, a consequence of common growth factors. *J Immunol* 2003; 170: 5583-5589.
52. Donnarumma G, Paoletti I, Biommino E, Orlando M, Tufano MA, Baroni A. *Malassezia furfur* induces the expression of beta-defensin-2 in human keratinocytes in a protein C-dependent manner. *Arch Dermatol Res* 2004; 295: 474-481.
53. Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: utilization of different signalling pathways by various bacterial species. *Infect Immun* 2004; 72: 352-358.
54. European Wound Management Association (EWMA). Position Document: Wound Bed Preparation in Practise. London: MEP Ltd, 2004.
55. Brehm H, Jacobs T, Vileikyte L, Weinberger S, Gibber M, Gill K, Tarnovskaya A, Entero H, Boulton AJ. Wound-healing protocols for diabetic foot and pressure ulcers. *Surg Technol Int* 2003; 11: 85-92.
56. Verdú Soriano J, Rueda López J, Martínez Cuervo F, Soldevilla Agreda J. Effect of an activated charcoal silver dressing on chronic wounds with no clinical signs of infection. *J Wound Care* 2004; 13: 419-423.
57. Thomas S, McCubbin P. A comparison of the antimicrobial effects of 10 silver-containing dressings. *J Wound Care* 2003; 12: 305-308.
58. Meaume S, Téot L, Lazareth I, Martini J, Bohbot S. The importance of pain reduction through dressing selection in routine wound management: the

- MAPP study. J Wound Care 2004; 13 : 409-413.
59. Wollina U. A hydropolymer dressing for chronic wounds: clinical experiences with 478 patients in an open multi-center trial. Anais Brasil Dermatol (Rio de Janeiro) 1997; 72: 527-532.
60. Cullen B, Watt PW, Lundqvist C, Silcock D, Schmidt RJ, Bogan D, Light ND. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol 2002; 34: 1544-1556.
61. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822-827.
62. Agren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 1999; 112: 463-469.
63. Weindl G, Schaller M, Schäfer-Korting M, Kortring HC. Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 2004; 17: 207-213.
64. Wollina U, Konrad H, Karamfilov T. Recessive epidermolysis bullosa dystrophicans (Hallopeau-Siemens) – improvement of wound healing by autologous epidermal grafts on an esterified hyaluronic acid membrane. J Dermatol (Tokyo) 2001; 28: 217-220.
65. Wollina U, Heinig B, Uhlemann C. Transdermal CO₂ application in chronic wounds.
66. International J Lower Extremity Wounds 2004; 3:103-106.